CSS
SPRO icon

Cubist Systematic Strategies’s Spero Therapeutics SPRO Stock Holding History

Cubist Systematic Strategies’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$76.8K Buy
40,845
+13,705
+50% +$30.1K ﹤0.01% 2807
2025
Q2 		$78.7K Buy
+27,140
New +$39K ﹤0.01% 2735
2022
Q2 		– Sell
-14,144
Closed -$123K – 4559
2022
Q1 		$123K Buy
+14,144
New +$145K ﹤0.01% 3189
2018
Q4 		– Sell
-1,006
Closed -$11K – 2264
2018
Q3 		$11K Buy
+1,006
New +$11.7K ﹤0.01% 1814

Other funds holding SPRO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's SPRO Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Spero Therapeutics (SPRO) stake by 50% in Q3 2025, buying an estimated $30.1K and bringing the position to 40,845 shares worth $76.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2807.

Cubist Systematic Strategies first reported a position in SPRO in Q3 2018 and has held it in 4 quarters since. The position peaked at $123K in Q1 2022. 47 funds tracked by Wall St. Rank hold SPRO as of Q3 2025.

  • Cubist Systematic Strategies held 40,845 shares of Spero Therapeutics worth $76.8K as of Q3 2025.
  • Cubist Systematic Strategies bought 13,705 Spero Therapeutics shares in Q3 2025, an estimated $30.1K.
  • Spero Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2807 holding.
  • Cubist Systematic Strategies first reported a position in Spero Therapeutics in Q3 2018 and has held it in 4 quarters since.
  • Cubist Systematic Strategies's Spero Therapeutics position peaked at $123K in Q1 2022.
  • 47 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.